What You Should Know
- Healthcare decision intelligence leader Lyric has announced the acquisition of Concert, a precision health payment accuracy innovator specializing in translating machine-readable clinical policies into real-time claims workflows.
- The transaction embeds Concert’s proprietary policy intelligence directly within Lyric42, Lyric’s AI-powered Healthcare Decision Intelligence Platform, expanding its scale amid a surge in advanced genetic testing and precision therapies.
- The acquisition represents the culmination of a deep operational partnership initiated in 2023, during which the scope and financial impact of their combined Diagnostics Module solution grew nearly tenfold.
- Backed by more than 35 years of clinical and policy expertise, Lyric commands an immense market footprint, supporting 200 million lives with nine of the top 10 U.S. health plans relying on its infrastructure to mitigate waste.
- Under the strategic direction of CEO Halsey Wise and President/CFO Ravi Umarji, the acquisition shifts the payer-provider dynamic from friction-heavy, retroactive enforcement to unified, transparent, and computable shared standards.
The Computable Policy Core
The primary technology architecture driving Lyric’s platform integration rejects flat, retroactive rule sheets to deliver an active orchestration layer that matches the velocity of modern clinical discovery. Founded in 2010 to bring much-needed structural transparency to the highly complex world of genetic testing, Concert spent over a decade building a definitive database of machine-readable clinical policy.
Within the integrated Lyric42 framework, this specialized coding and market intelligence engine is operationalized to streamline the entire laboratory claim lifecycle:
- Synchronized Policy Execution: The platform automatically unifies human-readable clinical criteria with computable, machine-readable digital code, ensuring policy decisions are updated dynamically as clinical evidence shifts.
- Frictionless Lab Triage: Operating via a comprehensive Diagnostics Module, the software evaluates multi-code outpatient laboratory claims in real time, delivering precise instruction sets directly to existing core systems.
- Responsible AI Orchestration: Advanced algorithmic models reconcile payment recommendations in milliseconds, structuring evidence and patterns to augment human decision-making without discarding administrative control.
- Traceable Audit Rationales: To protect health plans from legal liabilities, every automated payment recommendation is traceably linked to the exact underlying regulatory, policy, or clinical documentation behind it.
“Concert was built on the conviction that clinical and administrative policy should be transparent, evidence-based, and computable, delivered into the systems that health plans and providers actually use to make decisions,” stated Rob Metcalf, CEO of Concert. “Combining with Lyric allows us to deliver at scale through the Lyric42 platform.”
Strategic Prioritization: Driving Top-Line Growth and Value Creation
The immense commercial scale underlying Lyric’s infrastructure represents a powerful operational moat. Backed by over 35 years of clinical and payment analytics, Lyric’s platform currently supports 200 million individual lives, anchoring the claims workflows of nine of the top 10 U.S. health plans.
The acquisition of Concert is a deliberate expansion of a highly successful commercial partnership initiated in 2023, during which the scope and financial impact of their shared laboratory solutions grew nearly tenfold.
Under the leadership of CEO Halsey Wise—an experienced enterprise cloud leader who has guided six major health tech and software corporations—and President/CFO Ravi Umarji, the transaction delivers an immediate blueprint for sustainable margin preservation. By moving away from reactive billing enforcement at the back end, Lyric accelerates the pace of innovation across the ecosystem.
The combined platform reduces overall waste, lowers administrative overhead, and shields health plans from provider friction, while simultaneously protecting member access to high-value, precision diagnostics.
